| (AstraZeneca) D7230C00001 | A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT06106945 |
| (AstraZeneca) D7401C00001 / Soundtrack F1 | A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma | Dr Gwynivere Davies | Open to recruitment | NCT06549595 |
| (BeiGene) BGB-16673-302 | A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia Previously Exposed to Both BTK and BCL2 Inhibitors | Dr Christopher Hillis | Open to recruitment | NCT06846671 |
| (BeOne Medicines) BGB-11417-304 | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia | Dr Graeme Fraser | Open to recruitment | NCT07277231 |
| (CCTG) HD.12 / RADAR | A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma (RADAR) | Dr Joanne Britto | Open to recruitment | NCT04685616 |
| (CCTG) IND.244 | A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma | Dr Graeme Fraser | Open to recruitment | NCT05998642 |
| (CCTG) MY.13 | A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous AntiI-CD38 Antibody Therapy Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT06182774 |
| (CCTG) SC.26 / EASE | Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia | Dr Alejandro Garcia-Horton | Suspended/On hold | NCT04224974 |
| (Incyte) INCA34176-357 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Dr Alejandro Garcia-Horton | Open to recruitment | NCT06585774 |
| (Johnson & Johnson) 79635322MMY3001 / TRIlogy-4 | A Phase 3 Randomized Study Comparing JNJ-79635322 and an anti-BCMA Bispecific Antibody in Participants with Relapsed or Refractory Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD and an Anti-CD38 Antibody | Dr Hira Mian | Open to recruitment | NCT07258511 |
| (Merck) MK-2140-010 waveLINE-010 | MK-2140-010: A Randomized, Open-Label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) | Dr Tom Kouroukis | Open to recruitment | NCT067107347 |
| (Roche) CO46096 / CEVOLUTION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR LINE OF THERAPY | Dr Hira Mian | Open to recruitment | NCT07555938 |
| (SWOG) MYELOMATCH / CCTG ALC.7 | MYELOMATCH, MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS (NCT # NCT05564390) | Dr Alejandro Garcia-Horton | Open to recruitment | NCT05564390 |
| OCOG-2023-EMBRACE | A Study of Elranatamab Management with Outpatient and IntermittentDosing in Relapsed/Refractory Multiple Myeloma: EMBRACE Trial | Dr Hira Mian | Open to recruitment | NCT06421675 |
| (BMS) CA088-1007 / QUINTESSENTIAL-2 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma. | Dr Hira Mian | Open to recruitment | NCT06615479 |
| (CCTG) AL.6 / MM1YA-CTG01 | A measurable residual disease (MRD) focused, phase II study of Venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk acute myeloid leukemia: A TIER 1 MYELOMATCH SUBSTUDY | Dr Alejandro Garcia-Horton | Open to recruitment | NCT05554393 |
| (Janssen) 75276617AML3001 / cAMelot-2 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy | Dr Alejandro Garcia-Horton | Open to recruitment | NCT06852222 |
| (Kartos Therapeutics Inc.) KRT-232-115 / POIESIS | A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | Dr Shreyash Dalmia | Open to recruitment | NCT06479135 |
Find a Trial
Contact Us